Two overarching goals in chemical biology are finding ligands for every protein, and identifying the targets underlying phenotypically active compounds. For the last decade, these goals have been pursued empirically. We believe that there is a strong call for computational discovery in both enterprises. It is the long- term goal o this project to bring chemistry to a large community of biologists, by enabling docking screens against all structurally addressable targets, and by developing tools that identify the targets mediating phenotypic biological activity.
The first aim i s met by developing compound libraries, benchmarking sets, and web-based tools that radically reduce barriers to entry.
The second aim, target identification for ligands, is met by developing new chemoinformatic methods and testing them experimentally. 1. To elaborate ZINC with activity predictions using cheminformatics and docking, and link targets to disease. We will develop and deploy public access tools that enable biologists to interrogate chemistry for biology. 1. Tools in the ZINC platform will link commercially available compounds to their known and likely targets and, correspondingly, link targets to their known or likely ligands. 2. A new tool, DxTRx, connects targets to the phenotypes and diseases that they modulate. 3. We will use docking to precalculate high-scoring ligand lists for 10,000 relevant targets for which a structure exists. These hit-lists will be made available to the community, and will be substrates for our own target-target linkage studies. In short, we will develop an integrated tool set to allow an investigator to proceed from target ?? compound ?? phenotype??target in many areas of biology of active interest. 2. Predicting targets from ligands (SEA). We will further exploit SEA to interrogate pharmacology, and to improve the core method. We will A. Use SEA to reorganize target-family trees, such as for kinases, GPCRs, and ion channels, by ligand rather than sequence similarity. Early work portends a dramatic re- arborization, leading to testable hypotheses about new target-associations. B. Investigate a protein structure context for the ligand similarities. SEA now compares ligands by topology, with a statistical engine for significance. For many targets, structures exist, and it may be possible to add a receptor context to these calculations. C. Bringing back the receptor may also address a weakness of SEA, its dependence on known ligands. Exploiting work in aim 1, we will compare the proteome-wide docking hit lists, seeking new target- target associations. A new application is to D. We will use SEA to predict the targets of compounds active in whole organism phenotypic screens, expanding on existing collaborations.

Public Health Relevance

Virtual screening is widely used to discover new chemical tools and leads for drug discovery. Unfortunately, the technique remains difficult to use, and has thus been restricted to a few expert laboratories. Here, we create databases and tools to bring virtual screening to a wide biological audience, much expanding its impact and usefulness, and develop a chemoinformatics method to identify the 'on' and 'off' targets for drugs and reagents.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM071896-11
Application #
8910747
Study Section
Macromolecular Structure and Function D Study Section (MSFD)
Program Officer
Preusch, Peter
Project Start
2004-08-01
Project End
2016-05-31
Budget Start
2015-06-01
Budget End
2016-05-31
Support Year
11
Fiscal Year
2015
Total Cost
$334,641
Indirect Cost
$123,455
Name
University of California San Francisco
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Irwin, John J; Gaskins, Garrett; Sterling, Teague et al. (2018) Predicted Biological Activity of Purchasable Chemical Space. J Chem Inf Model 58:148-164
Maciejewski, Mateusz; Lounkine, Eugen; Whitebread, Steven et al. (2017) Reverse translation of adverse event reports paves the way for de-risking preclinical off-targets. Elife 6:
O'Meara, Matthew J; Ballouz, Sara; Shoichet, Brian K et al. (2016) Ligand Similarity Complements Sequence, Physical Interaction, and Co-Expression for Gene Function Prediction. PLoS One 11:e0160098
Farrell, Martilias S; McCorvy, John D; Huang, Xi-Ping et al. (2016) In Vitro and In Vivo Characterization of the Alkaloid Nuciferine. PLoS One 11:e0150602
Irwin, John J; Shoichet, Brian K (2016) Docking Screens for Novel Ligands Conferring New Biology. J Med Chem 59:4103-20
Sterling, Teague; Irwin, John J (2015) ZINC 15--Ligand Discovery for Everyone. J Chem Inf Model 55:2324-37
Barelier, Sarah; Sterling, Teague; O'Meara, Matthew J et al. (2015) The Recognition of Identical Ligands by Unrelated Proteins. ACS Chem Biol 10:2772-84
Huang, Xi-Ping; Karpiak, Joel; Kroeze, Wesley K et al. (2015) Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65. Nature 527:477-83
Yee, Sook Wah; Lin, Lawrence; Merski, Matthew et al. (2015) Prediction and validation of enzyme and transporter off-targets for metformin. J Pharmacokinet Pharmacodyn 42:463-75
Pimentel-Elardo, Sheila M; Sørensen, Dan; Ho, Louis et al. (2015) Activity-Independent Discovery of Secondary Metabolites Using Chemical Elicitation and Cheminformatic Inference. ACS Chem Biol 10:2616-23

Showing the most recent 10 out of 43 publications